Data mining and analysis of oxaliplatin-related adverse events of nervous system

FAN Baoxia; KONG Yan; LIU Ning; YANG Ping

doi:10.6039/j.issn.1001-0408.2024.03.15

您当前的位置：

首页 >

文章列表页 >

Data mining and analysis of oxaliplatin-related adverse events of nervous system

更新时间：2024-02-07

- Data mining and analysis of oxaliplatin-related adverse events of nervous system
- ZHONGGUO YAOFANG Vol. 35, Issue 3, Pages: 348-352(2024)
- 作者机构：
  
  1.济南市第四人民医院药学部，济南　250031
  2.山东中医药大学第二附属医院药学部，济南　250001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.03.15
  CLC： R969.3
- Published：15 February 2024，
  
  Received：10 August 2023，
  
  Revised：14 November 2023，
扫描看全文
范宝霞,孔燕,刘宁等.奥沙利铂相关神经系统不良事件数据挖掘与分析 ^Δ[J].中国药房,2024,35(03):348-352.

FAN Baoxia,KONG Yan,LIU Ning,et al.Data mining and analysis of oxaliplatin-related adverse events of nervous system[J].ZHONGGUO YAOFANG,2024,35(03):348-352.
范宝霞,孔燕,刘宁等.奥沙利铂相关神经系统不良事件数据挖掘与分析 ^Δ[J].中国药房,2024,35(03):348-352. DOI： 10.6039/j.issn.1001-0408.2024.03.15.

FAN Baoxia,KONG Yan,LIU Ning,et al.Data mining and analysis of oxaliplatin-related adverse events of nervous system[J].ZHONGGUO YAOFANG,2024,35(03):348-352. DOI： 10.6039/j.issn.1001-0408.2024.03.15.

摘要

目的

挖掘奥沙利铂相关神经系统不良事件（ADE），为临床安全用药提供参考。

方法

收集美国FDA不良事件报告系统（FAERS）2004年1月1日至2022年12月31日上报的奥沙利铂相关神经系统ADE数据。采用报告比值比法和比例报告比值法进行数据挖掘，利用国际医学用语词典（MedDRA）（26.0版）药物ADE术语集中的系统器官分类、高位组语（HLGT）、首选术语（PT）进行分类统计。

结果

共检索到各类神经系统疾病的奥沙利铂相关ADE报告7 266例，共挖掘出100个PT。其中，57个PT为奥沙利铂说明书中未记载的ADE信号。这些报告中，男性（46.85%）多于女性（42.98%），年龄以45～＜75岁（65.22%）为主，意大利报告数量最多（16.32%）；严重ADE以导致住院或住院时间延长为主（38.16%）。报告数排名前5位的PT分别为周围神经病、异常感觉、神经毒性、意识丧失、构音不良；信号强度排名前5位的PT分别为对冷有异样感觉、神经肌肉强直、急性多发性神经病、神经元神经病、轴索和脱髓鞘多发神经病。报告共涉及13个HLGT，以神经类疾病（不另分类）信号数最多（29个）。

结论

临床在使用奥沙利铂时，不仅要监护发生率较高的急性、慢性周围神经病变，也要关注患者意识状态、神经病学症状，警惕格林巴利综合征、莱尔米特征、可逆性后部白质脑病综合征、高血氨性脑病等罕见不良反应，以确保患者用药安全。

Abstract

OBJECTIVE

To provide reference for clinically safe drug use by mining oxaliplatin-related adverse drug events （ADE） of the nervous system.

METHODS

Oxaliplatin-related neurologic ADE data reported by the FDA adverse event reporting system （FAERS） between January 1st， 2004 and December 31st， 2022 were collected. The reporting odds ratio and proportional reporting ratio were used for data mining. The data were classified statistically by using systematic organ classification， high-level group term （HLGT） and preferred term （PT） in the MedDRA （version 26.0）.

RESULTS

A total of 7 266 cases of oxaliplatin-related ADE， which were classified as various neurological， were retrieved， and 100 PT were identified. Of these， fifty-seven PT were unspecified adverse reaction signals in the manual. Among these reports， males （46.85%） were more than females （42.98%）， the age of patients was 45-＜75 years （65.22%）， the number of reports was highest in Italy （16.32%）， and the severe type was hospitalization or prolonged hospitalization （38.16%）. The top 5 PT reports in the list of case number were peripheral neuropathy， paresthesia， neurotoxicity， loss of consciousness and dysarthria. The top 5 PT reports in the list of signal intensities were cold-induced paresthesia， neuromuscular rigidity， acute polyneuropathy， neuronal neuropathy， axonal and demyelinating polyneuropathy. A total of 13 HLGT were involved， with neurological diseases （not classified separately） having the highest number of signals （29）.

CONCLUSIONS

When using oxaliplatin in clinical practice， it is not only necessary to monitor the high incidence of acute and chronic peripheral neuropathy， but also to pay attention to the patient’s consciousness state and neurological symptoms. We should pay attention to the rare types of adverse reactions， such as guillain-barre syndrome， Lhermitte sign， posterior reversible encephalopathy syndrome， and hyperammoniacal encephalopathy， so as to ensure the safety of medication.

关键词

奥沙利铂神经系统毒性药品不良反应信号挖掘

Keywords

neurotoxicityadverse drug reactionssignal mining

references

KANG L M，TIAN Y Y，XU S L，et al. Oxaliplatin-induced peripheral neuropathy：clinical features，mechanisms，prevention and treatment[J]. J Neurol，2021，268（9）：3269-3282.

于佳鑫，李小平，葸风林，等. 奥沙利铂引起可逆性后部白质脑病综合征药品不良反应的文献分析[J]. 中国临床药理学杂志，2023，39（4）：578-582.

YU J X，LI X P，XI F L，et al. Literature analysis of oxaliplatin induced adverse drug reaction of posterior rever-sible encephalopathy syndrome[J]. Chin J Clin Pharmacol，2023，39（4）：578-582.

SYMEONIDIS D G，LIATSOS A D，MAZLIMOGLOU E K，et al. Posterior reversible encephalopathy syndrome associated with oxaliplatin use for pancreatic adenocarcinoma[J]. Case Rep Oncol，2021，14（2）：838-844.

薄明明，石亚飞，孙继雄，等. 基于美国FAERS数据库的培唑帕尼不良事件信号挖掘与分析[J]. 中国药房，2023，34（15）：1879-1883.

BO M M，SHI Y F，SUN J X，et al. Signals mining and analysis of adverse drug events of pazopanib based on FAERS database[J]. China Pharm，2023，34（15）：1879-1883.

杨眉，严明芳，林雅，等. 奥沙利铂致周围神经病变的危险因素分析[J]. 中外医疗，2021，40（35）：143-146.

YANG M，YAN M F，LIN Y，et al. Analysis of risk factors of oxaliplatin-induced peripheral neuropathy[J]. China Foreign Med Treat，2021，40（35）：143-146.

HERSHMAN D L，TILL C，WRIGHT J D，et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials[J]. J Clin Oncol，2016，34（25）：3014-3022.

BURGESS J，FERDOUSI M，GOSAL D，et al. Chemotherapy-induced peripheral neuropathy：epidemiology，pathomechanisms and treatment[J]. Oncol Ther，2021，9（2）：385-450.

YANG Y，ZHAO B，GAO X J，et al. Targeting strategies for oxaliplatin-induced peripheral neuropathy：clinical syndrome，molecular basis，and drug development[J]. J Exp Clin Cancer Res，2021，40（1）：331.

PARK S B，LIN C S Y，KIERNAN M C. Nerve excitability assessment in chemotherapy-induced neurotoxicity[J]. J Vis Exp，2012（62）：3439.

PAPPA E，BERZERO G，HERLIN B，et al. Guillain-barré syndrome during platinum-based chemotherapy：a case series and review of the literature[J]. Oncologist，2020，25（1）：e194-e197.

YOON J Y，NAM T S，KIM M K，et al. Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy[J]. Asia Pac J Clin Oncol，2012，8（2）：201-204.

NARDONE R，BURATTI T，GOLASZEWSKI S，et al. Delayed oxaliplatin-induced sensorimotor polyneuropathy[J]. Onkologie，2009，32（5）：283-285.

BENCARDINO K，MAURI G，AMATU A，et al. Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge：single institution series and systematic review study[J]. Clin Colorectal Cancer，2016，15（3）：213-221.

AMARANENI A，SETH A，ITAWI E A，et al. Oxaliplatin-induced Lhermitte sign. A case report and review of literature[J]. Clin Colorectal Cancer，2014，13（4）：257-259.

TAIEB S，TRILLET-LENOIR V，RAMBAUD L，et al. Lhermitte sign and urinary retention：atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer，2002，94（9）：2434-2440.

陈琳，王海霞，陈邓林，等. 奥沙利铂联合氟尿嘧啶化疗致可逆性后部白质脑病综合征1例[J]. 中国医院药学杂志，2023，43（16）：1882-1884.

CHEN L，WANG H X，CHEN D L，et al. Reversible po- sterior leukoencephalopathy syndrome after treatment with oxaliplatin and 5-Fluorouracil：a case report[J]. Chin J Hosp Pharm，2023，43（16）：1882-1884.

LI K H，YANG Y，GUO D J，et al. Clinical and MRI features of posterior reversible encephalopathy syndrome with atypical regions：a descriptive study with a large sample size[J]. Front Neurol，2020，11：194.

BRANCA J J V，MARESCA M，MORUCCI G，et al. Oxaliplatin-induced blood brain barrier loosening：a new point of view on chemotherapy-induced neurotoxicity[J]. Oncotarget，2018，9（34）：23426-23438.

FEDERICO A D，NUVOLA G，SISI M，et al. Hyperammonemic encephalopathy during XELOX regimen. is it capecitabine or oxaliplatin responsible?[J]. Anticancer Drugs，2020，31（10）：1103-1105.

OGATA T，SATAKE H，OGATA M，et al. Oxaliplatin-induced hyperammonemic encephalopathy in a patient with metastatic pancreatic cancer：a case report[J]. Case Rep Oncol，2017，10（3）：885-889.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal mining and analysis of adverse drug event signals of darolutamide

Risk signal mining of ixazomib based on the database of FAERS

Mining and analysis of lorlatinib-induced adverse drug event signals

Data-mining of Adverse Drug Events Signals for Tocilizumab Based on US FAERS Database

ADR Signal Mining of Rivaroxaban Based on FDA Adverse Event Reporting Database

Related Author

KANG Jian

CHEN Jinhua

QIAO Lijuan

ZHANG Jianping

XU Rong

ZHAO Xincai

YANG Li

HUANG Mengwen

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Zhengzhou University

Dept. of Pharmacy， the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital

Dept. of Pharmacy， Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Dept. of Pharmacy， Chengdu Fifth People’s Hospital

School of Pharmacy， Chengdu University of Traditional Chinese Medicine

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰